**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 65881

**Manuscript Type:** CASE REPORT

***FGFR2-TSC22D1*, a novel *FGFR2* fusion gene identified in a patient with colorectal cancer: A case report**

Kao XM *et al*. A novel *FGFR2* fusion in CRC

Xiao-Ming Kao, Xi Zhu, Jun-Ling Zhang, Shi-Qing Chen, Chao-Gang Fan

**Xiao-Ming Kao, Xi Zhu,** Department of General Surgery, Jinling Hospital, Nanjing 210002, Jiangsu Province, China

**Jun-Ling Zhang, Shi-Qing Chen,** Department of Medical, 3D Medicines Inc., Shanghai 201114, China

**Chao-Gang Fan,** Department of General Surgery, The Affiliated BenQ Hospital of Nanjing Medical University, Nanjing 210002, Jiangsu Province, China

**Author contributions:** Fan CG performed the conception and design of the study; Kao XM and Zhu X performed the acquisition of clinical data; Zhang JL and Chen SQ performed the analysis and interpretation of the data; Fan CG and Kao XM performed the manuscript drafting and revision; all authors performed the final approval of the manuscript.

**Corresponding author: Chao-Gang Fan, PhD, Chief Doctor,** Department of General Surgery, The Affiliated BenQ Hospital of Nanjing Medical University, No. 71 Hexi Street, Jianye District, Nanjing 210002, Jiangsu Province, China. fancg2002@hotmail.com

**Received:** March 17, 2021

**Revised:** April 13, 2021

**Accepted:** June 28, 2021

**Published online:**

**Abstract**

BACKGROUND

The FGFR signaling pathway is activated in multiple tumor types through gene amplifications, single base substitutions, or gene fusions. Novel *FGFR* gene fusions may represent candidate targets for the development of tyrosine kinase inhibitors.

CASE SUMMARY

Herein, we report a patient with colorectal cancer (CRC) harboring a novel *FGFR2* fusion gene. A 59-year-old man felt discomfort in his right upper abdomen with loss of appetite for 6 mo. An abdominal computed tomography scan revealed the existence of a space-occupying lesion in the ascending colon. The pathological diagnosis was a poorly differentiated adenocarcinoma. Subsequent biopsy specimen was subjected to next-generation sequencing analysis, and a novel *FGFR2-TSC22D1* fusion with complete kinase structure of FGFR2 protein was identified.

CONCLUSION

We report the first case of CRC harboring *FGFR2-TSC22D1,* which enriches the *FGFR2* fusion spectrum. FGFR2 inhibitors might be effective in the later treatment for this patient.

**Key Words:** *FGFR2-TSC22D1*; Colorectal cancer; Next-generation sequencing; Case report

Kao XM, Zhu X, Zhang JL, Chen SQ, Fan CG. *FGFR2-TSC22D1*, a novel *FGFR2* fusion gene identified in a patient with colorectal cancer: A case report. *World J Clin Cases* 2021; In press

**Core Tip:** A colorectal cancer patient had a novel *FGFR2-TSC22D1* fusion which included exons 1-17 of *FGFR2* and exons 3 of *TSC22D1*. This fusion contains *FGFR2* kinase domain and coil coiled domains encoded by *TSC22D1* exon 3, which might induce oncogenesis. Our case enriches the *FGFR2* fusion spectrum. We believe that these novel findings have important implications in the strategy development of therapy for colorectal cancer.

**INTRODUCTION**

Colorectal cancer (CRC) is one of the most common causes of cancer-related death worldwide and the 3rd most common cancer in males[1]. In recent years, the burden of CRC is increasing rapidly in China[2]. With the advent of targeted drugs such as epidermal growth factor or vascular endothelial growth factor tyrosine kinase inhibitors (TKIs), the overall survival of CRC increased from the past 8-12 mo to 30 mo nowadays[3-5].

*FGFR* fusions in solid tumors are caused by chromosomal rearrangements. FGFR families includes FGFR1-4, four highly conserved receptor tyrosine kinases, among which FGFR2 has been proven to be a potential target of FGFR TKI inhibitors. At the same time, in many solid tumors, such as urothelial carcinomas and intrahepatic cholangiogarcinomas, FGFR activating molecular alterations (including *FGFR3* mutations and *FGFR2* fusions) have been found, expanding the options for patients who may benefit from FGFR inhibitors[6]. With the development of next generation sequencing (NGS), some uncommon genomic mutations are detected, such as *FGFR2-PPHLN1*[7], *FGFR2-BICC1*[8], and *FGFR2-CCDC6* fusion mutations[9]. In this case, with the help of NGS detection technology, we found a CRC patient carrying a rare *FGFR2-TSC22D1* fusion gene, which further expanded the *FGFR2* fusion variant spectrum.

**CASE PRESENTATION**

***Chief complaints***

A 59-year-old male patient with right upper quadrant pain and discomfort, and no appetite for 6 mo, was referred to our hospital for further treatment.

***History of present illness***

Six months ago, the patient developed right upper abdominal distension, pain, and discomfort without obvious inducement, accompanied by anorexia. No nausea, vomiting, chills, high fever, palpitation, shortness of breath, or yellow staining of skin and mucous membrane was noted. At a local hospital, colorectal examination revealed an ulcerative mass in the liver flexure of the ascending colon. There was a 0.6 cm × 0.6 cm polyp in the middle of the transverse colon. Pathological report suggested that the ascending colon mass was poorly differentiated adenocarcinoma.

***Physical examination***

Physical examination revealed that the patient’s body temperature was 36.8 °C, heart rate 78 bpm/min, respiratory 16 bpm/min, and blood pressure 122/78 mmHg.

***Laboratory examinations***

The white cell count was 9.46 × 109/L, hemoglobin was 62 g/mL , and platelet count was 451 × 109/L. Serum tumor markers carcinoembryonic antigen (7.58 ng/mL), carbohydrate antigen (CA)19-9 (21.63 U/mL), CA125 (44.85 U/mL), CA242 (21.57 IU/mL), CA724 (8.38 IU/mL), and CA153 (4.59 IU/mL) were detectable.

The pathological diagnosis under ascending colonoscopy was poorly differentiated adenocarcinoma (cT4N+M0, Figure 1).

The tissue biopsy specimens were then analyzed by NGS and a rare intergenic region between *FGFR2* and *TSC22D1* fusion variation was detected (Figure 2A and B). *TSC22D1* (TSC22 domain family protein 1) gene is a transcription factor belonging to a large family of early response. Dimers of TSC22D1 act as a transcription factor and have tumor suppressor function. The *FGFR2-TSC22D1* fusion gene includes exons 1-17 of *FGFR2* and exons 3 of *TSC22D1*, retaining the complete kinase structure of FGFR2. The ratio of FAM-positivity (*FGFR2* gene) to VIC (internal reference gene) was 0.0048 in droplet digital polymerase chain reaction (ddPCR), indicating weakly *FGFR2* expression (Figure 2C) and proving that *FGFR2* was positive.

***Imaging examinations***

A computed tomography scan of the abdomen showed the presence of a space-occupying lesion in the liver flexure of the ascending colon.

**FINAL DIAGNOSIS**

The patient was finally diagnosed as having stage cT4N+M0 CRC and carrying the novel *FGFR2-TSC22D1* fusion gene.

**TREATMENT**

Based on pathological staging, the patient was given preoperative chemotherapy for tumor down-staging. The regimen is oxaliplatin (200 mg, D1, intravenous drips) plus capecitabine (1500 mg, D1-14, oral). After six cycles of preoperative chemotherapy, the patient underwent radical resection for CRC.

**OUTCOME AND FOLLOW-UP**

Postoperative pathology showed that no residual cells were found in the duodenal wall, which suggested that a pathological complete response has been achieved.

**DISCUSSION**

*FGFR2* fusions have been identified as a novel oncogenic target for drug development in a number of cancers including breast cancer[10] and intrahepatic cholangiocarcinoma[7-9]. Interestingly, a novel *FGFR2* gene fusion was identified in the CRC patient reported in this paper, suggesting that this event may represent a new candidate therapeutic target for which similar strategies could be used in the clinical management.

A comprehensive understanding of *FGFR2* fusion information seems to be necessary. NGS could be used as a supplementary method for *FGFR2* variation for high-throughput molecular analysis, while detecting gene copy number alterations, fusions, insertions, and deletions simultaneously.

**CONCLUSION**

In our case, a rare *FGFR2* fusion gene, confirmed by ddPCR, was found, which enriched the *FGFR2* fusion spectrum. FGFR2 inhibitors might be effective in the later treatment for this patient.

**REFERENCES**

1 **Dekker E**, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. *Lancet* 2019; **394**: 1467-1480 [PMID: 31631858 DOI: 10.1016/S0140-6736(19)32319-0]

2 **Feng RM**, Zong YN, Cao SM, Xu RH. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? *Cancer Commun (Lond)* 2019; **39**: 22 [PMID: 31030667 DOI: 10.1186/s40880-019-0368-6]

3 **Heinemann V**, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, Jung A, Stintzing S. FOLFIRI plus cetuximab *vs* FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. *Lancet Oncol* 2014; **15**: 1065-1075 [PMID: 25088940 DOI: 10.1016/S1470-2045(14)70330-4]

4 **Van Cutsem E**, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. *J Clin Oncol* 2011; **29**: 2011-2019 [PMID: 21502544 DOI: 10.1200/JCO.2010.33.5091]

5 **Loupakis F**, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. *N Engl J Med* 2014; **371**: 1609-1618 [PMID: 25337750 DOI: 10.1056/NEJMoa1403108]

6 **Facchinetti F**, Hollebecque A, Bahleda R, Loriot Y, Olaussen KA, Massard C, Friboulet L. Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors. *Clin Cancer Res* 2020; **26**: 764-774 [PMID: 31585937 DOI: 10.1158/1078-0432.CCR-19-2035]

7 **Sia D**, Losic B, Moeini A, Cabellos L, Hao K, Revill K, Bonal D, Miltiadous O, Zhang Z, Hoshida Y, Cornella H, Castillo-Martin M, Pinyol R, Kasai Y, Roayaie S, Thung SN, Fuster J, Schwartz ME, Waxman S, Cordon-Cardo C, Schadt E, Mazzaferro V, Llovet JM. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. *Nat Commun* 2015; **6**: 6087 [PMID: 25608663 DOI: 10.1038/ncomms7087]

8 **Ying X**, Tu J, Wang W, Li X, Xu C, Ji J. *FGFR2-BICC1*: A Subtype Of *FGFR2* Oncogenic Fusion Variant In Cholangiocarcinoma And The Response To Sorafenib. *Onco Targets Ther* 2019; **12**: 9303-9307 [PMID: 31807010 DOI: 10.2147/OTT.S218796]

9 **Wang Y**, Ding X, Wang S, Moser CD, Shaleh HM, Mohamed EA, Chaiteerakij R, Allotey LK, Chen G, Miyabe K, McNulty MS, Ndzengue A, Barr Fritcher EG, Knudson RA, Greipp PT, Clark KJ, Torbenson MS, Kipp BR, Zhou J, Barrett MT, Gustafson MP, Alberts SR, Borad MJ, Roberts LR. Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein. *Cancer Lett* 2016; **380**: 163-173 [PMID: 27216979 DOI: 10.1016/j.canlet.2016.05.017]

10 **Wu YM**, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, Lonigro RJ, Vats P, Wang R, Lin SF, Cheng AJ, Kunju LP, Siddiqui J, Tomlins SA, Wyngaard P, Sadis S, Roychowdhury S, Hussain MH, Feng FY, Zalupski MM, Talpaz M, Pienta KJ, Rhodes DR, Robinson DR, Chinnaiyan AM. Identification of targetable FGFR gene fusions in diverse cancers. *Cancer Discov* 2013; **3**: 636-647 [PMID: 23558953 DOI: 10.1158/2159-8290.CD-13-0050]

**Footnotes**

**Informed consent statement:** Informed written consent was obtained from the patient for publication of this report and any accompanying images.

**Conflict-of-interest statement:** JZ and SC were employed by Shanghai 3D Medicines Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** March 17, 2021

**First decision:** April 4, 2021

**Article in press:**

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A, A

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Kraja F, Valiveti CK **S-Editor:** Fan JR **L-Editor:** Wang TQ **P-Editor:**

**Figure Legends**



**Figure 1 Pathological detection.** A: Hematoxylin and eosin staining; B: Abdominal computed tomography showed a tumor lesion in the ascending colon.



**Figure 2** **Next-generation sequencing and droplet digital polymerase chain reaction findings for the primary tissue sample.** A: A novel intergenic region between *FGFR2* exons 1-17 and *TSC22D1* exon 3 was identified; B: Next-generation sequencing results showing the breakpoint of the *FGFR2-TSC22D1* fusion; C: Droplet digital polymerase chain reaction (ddPCR) amplification charts. Ch1 is FAM Channel (mutant type) and Ch2 is VIC channel (wild type). In these charts, black points represent PCR negative droplets, and blue and green points represent PCR positive droplets in FAM channel and VIC channel, respectively.